

# Marc A Dall'era

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3497244/publications.pdf>

Version: 2024-02-01

45  
papers

2,009  
citations

516710

16  
h-index

289244

40  
g-index

47  
all docs

47  
docs citations

47  
times ranked

3352  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	1.9	638
2	Active Surveillance for Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2012, 62, 976-983.	1.9	518
3	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	1.9	235
4	Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. <i>Nature Communications</i> , 2018, 9, 4700.	12.8	71
5	Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. <i>BJU International</i> , 2011, 107, 1232-1237.	2.5	67
6	A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. <i>Cancer</i> , 2016, 122, 1897-1904.	4.1	47
7	Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men. <i>American Journal of Preventive Medicine</i> , 2018, 55, S103-S111.	3.0	45
8	Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. <i>Scientific Reports</i> , 2021, 11, 6377.	3.3	38
9	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	1.6	29
10	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. <i>Journal of Urology</i> , 2015, 193, 436-442.	0.4	27
11	Germline and somatic DNA repair gene alterations in prostate cancer. <i>Cancer</i> , 2020, 126, 2980-2985.	4.1	24
12	Ultrasensitive Prostate Specific Antigen and its Role after Radical Prostatectomy: A Systematic Review. <i>Journal of Urology</i> , 2015, 193, 1525-1531.	0.4	22
13	Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. <i>Scientific Reports</i> , 2017, 7, 12277.	3.3	21
14	Regulation of u-PA gene expression in human prostate cancer. <i>International Journal of Cancer</i> , 2001, 94, 390-395.	5.1	19
15	Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. <i>Nature Reviews Urology</i> , 2008, 5, 277-283.	1.4	17
16	Contemporary management of muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 941-950.	2.4	17
17	Outcomes and follow-up strategies for patients on active surveillance. <i>Current Opinion in Urology</i> , 2009, 19, 258-262.	1.8	16
18	Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. <i>European Urology Focus</i> , 2019, 5, 1014-1021.	3.1	15

#	ARTICLE	IF	CITATIONS
19	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	1.6	15
20	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022, 207, 70-76.	0.4	15
21	Pretreatment Imaging Can Be Used to Select Imaging Guidance, Ultrasound Alone Versus CT Plus Ultrasound, for Percutaneous Renal Radiofrequency Ablation. <i>American Journal of Roentgenology</i> , 2011, 197, 1244-1250.	2.2	14
22	Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. <i>BJU International</i> , 2019, 124, 730-737.	2.5	14
23	Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. <i>Cancer</i> , 2018, 124, 1921-1928.	4.1	12
24	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	2.5	10
25	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	2.5	10
26	<scp>DGCR</scp> 8 is essential for tumor progression following <scp>PTEN</scp> loss in the prostate. <i>EMBO Reports</i> , 2015, 16, 1219-1232.	4.5	9
27	Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. <i>World Journal of Urology</i> , 2017, 35, 277-283.	2.2	8
28	Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1760-1762.	1.6	6
29	Liquid biomarkers in active surveillance. <i>World Journal of Urology</i> , 2022, 40, 21-26.	2.2	6
30	Utilization and Yield of CT Urography: Are the American Urological Association Guidelines for Imaging of Patients With Asymptomatic Microscopic Hematuria Being Followed?. <i>American Journal of Roentgenology</i> , 2021, 216, 106-110.	2.2	4
31	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	2.2	4
32	A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome. <i>Canadian Urological Association Journal</i> , 2017, 11, E344-9.	0.6	3
33	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	1.6	3
34	Reasons for Abandonment of Active Surveillance in Men with Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 637-638.	0.4	2
35	Utility of Intraprocedural Contrast-Enhanced CT in Ablation of Renal Masses. <i>American Journal of Roentgenology</i> , 2020, 214, 122-128.	2.2	2
36	The optimal management of clinically localized prostate cancer: the debate continues. <i>Nature Reviews Urology</i> , 2007, 4, 474-475.	1.4	1

#	ARTICLE	IF	CITATIONS
37	What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?. Journal of Urology, 2015, 194, 615-616.	0.4	1
38	Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 58-63.	1.9	1
39	Multiparametric <scp>MRI</scp>: an important tool to improve risk stratification for active surveillance in prostate cancer. BJU International, 2018, 122, 721-722.	2.5	1
40	Editorial Comment. Journal of Urology, 2017, 198, 328-328.	0.4	0
41	Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. Journal of Urology, 2017, 197, 8-9.	0.4	0
42	New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose?. European Urology, 2018, 74, 549-550.	1.9	0
43	Reply to Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?. Cancer, 2018, 124, 3619-3620.	4.1	0
44	Editorial Comment. Journal of Urology, 2019, 201, 935-936.	0.4	0
45	Editorial Comment. Journal of Urology, 2020, 204, 1194-1194.	0.4	0